GT Biologics

GT Biologics is developing naturally occurring human bacteria as next generation biotherapeutics for autoimmune conditions, such as Crohn’s disease.

Bacteria that occur naturally in the human gut play a critical role in the development and maintenance of a healthy immune system. GT Biologics has been able to elucidate the molecular mechanisms by which certain species of bacteria influence the immune system and shown how they play an important role in suppressing certain pathways that can give rise to autoimmune conditions, such as Irritable Bowel Disease and Multiple Sclerosis. Their approach is very different from traditional probiotic development, as it is based on mechanistic understanding of therapeutic action and the development of regulated medical products. Having generated IP around specific strains of bacteria, the company is poised to commence pre-clinical and clinical development of its lead product for Crohn’s disease. In addition, the company has a proven technology platform capable of generating a pipeline of therapies for other autoimmune conditions.